Analysts Set Humana Inc. (NYSE:HUM) Price Target at $288.60

Humana Inc. (NYSE:HUM - Get Free Report) has been assigned a consensus rating of "Hold" from the twenty-three ratings firms that are currently covering the stock, MarketBeat.com reports. Seventeen investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $284.90.

A number of equities analysts recently commented on HUM shares. Guggenheim initiated coverage on Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price target for the company. Barclays boosted their price objective on Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a report on Friday, April 11th. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and set a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Finally, Morgan Stanley reduced their price objective on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th.

Humana Stock Down 7.4 %

Shares of NYSE:HUM traded down $21.20 during midday trading on Tuesday, reaching $264.41. The company had a trading volume of 3,670,273 shares, compared to its average volume of 1,759,722. Humana has a 1-year low of $213.31 and a 1-year high of $406.46. The stock has a market cap of $31.91 billion, a PE ratio of 26.57, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business's 50 day moving average price is $265.90 and its 200 day moving average price is $270.22.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Research analysts forecast that Humana will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.34%. Humana's dividend payout ratio (DPR) is currently 35.58%.

Institutional Trading of Humana

Hedge funds have recently bought and sold shares of the company. Clarius Group LLC raised its position in Humana by 63.1% in the 1st quarter. Clarius Group LLC now owns 1,476 shares of the insurance provider's stock worth $391,000 after purchasing an additional 571 shares during the period. Rakuten Securities Inc. grew its position in Humana by 50.0% during the 1st quarter. Rakuten Securities Inc. now owns 300 shares of the insurance provider's stock worth $79,000 after acquiring an additional 100 shares during the last quarter. QRG Capital Management Inc. increased its stake in Humana by 29.0% in the 1st quarter. QRG Capital Management Inc. now owns 2,765 shares of the insurance provider's stock worth $732,000 after purchasing an additional 621 shares during the period. Janney Montgomery Scott LLC purchased a new stake in shares of Humana during the first quarter valued at approximately $1,309,000. Finally, Bank Pictet & Cie Europe AG bought a new position in shares of Humana in the first quarter worth approximately $214,000. Institutional investors own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.